Advertisement
by Ed Susman

In the largest trial ever conducted using cardiac magnetic resonance imaging, doctors said they observed an infarct size of 16 percent of the left ventricle using intracoronary delivery and 17 percent using IV administration of abciximab (P=0.52).

"This study demonstrates that, in ST-elevated myocardial infarction patients, intracoronary abciximab did not result in a difference in myocardial damage and/or reperfusion," said Jochen Wöhrle, MD, professor of medicine at the University of Ulm, Germany, in his presentation at the Transcatheter Cardiovascular Therapeutics annual meeting.

Continue reading...

Advertisement
Advertisement